https://ipharmag.com/article/novo-nordisk-hengrui-oral-weekly-obesity-pill-deal iPharmag en 2026-09-30T03:50:00+00:00 Novo Nordisk Pays $300M Upfront for a Once-Weekly Obesity Pill From China’s Hengrui https://ipharmag.com/article/leqembi-vs-kisunla-alzheimers-drugs-compared iPharmag en 2026-09-30T03:50:00+00:00 Leqembi vs. Kisunla: How the Two Alzheimer’s Antibody Drugs Compare https://ipharmag.com/article/astrazeneca-summit-2b-ivonescimab-gi-cancer-collaboration iPharmag en 2026-09-30T03:50:00+00:00 AstraZeneca Invests $2 Billion in Summit to Pair Ivonescimab With Its Cancer ADCs https://ipharmag.com/article/trumprx-explained-drugs-prices-how-it-works iPharmag en 2026-09-29T00:41:17+00:00 What Is TrumpRx? How the Drug-Price Site Works, What’s on It, and Who Can Use It https://ipharmag.com/article/fda-approves-gazyva-childhood-nephrotic-syndrome-relapse iPharmag en 2026-09-29T00:41:17+00:00 First New Treatment in 70 Years: FDA Approves Gazyva to Prevent Nephrotic Syndrome Relapses https://ipharmag.com/article/fda-approves-abbvie-juvmo-tavapadon-parkinsons iPharmag en 2026-09-29T00:41:17+00:00 FDA Approves AbbVie’s Juvmo, a New Kind of Once-Daily Parkinson’s Pill